Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 4Phase 3 3

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Breast 1

Conditions

Ovarian Neoplasms 4Triple Negative Breast Neoplasms 2Solid Tumor 2Neoplasms 2Stomach Neoplasms 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Advanced Solid Tumor 1Advanced Cancer 1

Interventions

Paclitaxel 68Carboplatin 64pembrolizumab 32Cyclophosphamide 32Bevacizumab 27liposomal doxorubicin 24Cisplatin 24Topotecan 21Gemcitabine 21olaparib 18fludarabine 17Taxes 16Docetaxel 15Nivolumab 14Doxorubicin 14niraparib 13veliparib 12Albumin-Bound Paclitaxel 11aldesleukin 9Filgrastim 9fludarabine phosphate 8durvalumab 8Oxaliplatin 8Fluorouracil 8Drug Therapy 8sargramostim 7Peripheral Blood Stem Cell Transplantation 7Magnetic Resonance Spectroscopy 7Leucovorin 7talazoparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Ovarian Neoplasms × fluzoparib × Clear all
NCT04718740 2023-08-14

A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
33 enrolled
Gynecologic

Ovarian Neoplasms

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
98 enrolled
BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03509636 2022-07-01

A Study of Fluzoparib(SHR-3162)in BRCA1/2-mutant Relapsed Ovarian Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
113 enrolled
Gynecologic

Ovarian Neoplasms

NCT02575651 2019-06-17

A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
79 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡